

# Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/I96E94B7AAEEN.html>

Date: November 2021

Pages: 38

Price: US\$ 125.00 (Single User License)

ID: I96E94B7AAEEN

## Abstracts

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which focuses on the development of vaccines in the area of immune-oncology. The company develops immunotherapies that activates immune system of cancer patients to identify and eradicate tumors. The company's pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene's lead product candidate, CF33 is a chimeric vaccinia poxvirus for treatment of mixed advanced solid tumours (MAST) and metastatic triple negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales, Australia.

### Imugene Ltd Key Recent Developments

Jun 10,2021: Imugene appoints Dr Monil Shah as Chief Business Officer

Apr 23,2021: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2021

Dec 10,2020: Imugene receives \$4.82 million R&D tax incentive

Sep 30,2020: Imugene appoints Dr Rita Laeufle as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Imugene Ltd - Key Facts  
Imugene Ltd - Key Employees  
Imugene Ltd - Key Employee Biographies  
Imugene Ltd - Major Products and Services  
Imugene Ltd - History  
Imugene Ltd - Company Statement  
Imugene Ltd - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Imugene Ltd - Business Description  
Imugene Ltd - SWOT Analysis  
SWOT Analysis - Overview  
Imugene Ltd - Strengths  
Imugene Ltd - Weaknesses  
Imugene Ltd - Opportunities  
Imugene Ltd - Threats  
Imugene Ltd - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Imugene Ltd, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Jun 10, 2021: Imugene appoints Dr Monil Shah as Chief Business Officer

Apr 23, 2021: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2021

Dec 10, 2020: Imugene receives \$4.82 million R&D tax incentive

Sep 30, 2020: Imugene appoints Dr Rita Laeufle as Chief Medical Officer

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Imugene Ltd, Key Facts  
Imugene Ltd, Key Employees  
Imugene Ltd, Key Employee Biographies  
Imugene Ltd, Major Products and Services  
Imugene Ltd, History  
Imugene Ltd, Subsidiaries  
Imugene Ltd, Key Competitors  
Imugene Ltd, Ratios based on current share price  
Imugene Ltd, Annual Ratios  
Imugene Ltd, Annual Ratios (Cont...1)  
Imugene Ltd, Interim Ratios  
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Imugene Ltd, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Imugene Ltd, Performance Chart (2017 - 2021)

Imugene Ltd, Ratio Charts

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/I96E94B7AAEEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I96E94B7AAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970